Burmester, G. R., Galloway, J., Bevers, K., Avouac, J., Romero-Yuste, S., Caporali, R. F., . . . Verschueren, P. (2026). Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies. Rheumatology and Therapy, 13(5), 1287. https://doi.org/10.1007/s40744-026-00874-x
Παραπομπή σε μορφή Chicago (17η εκδ.)Burmester, Gerd R., et al. "Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and Up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies." Rheumatology and Therapy 13, no. 5 (2026): 1287. https://doi.org/10.1007/s40744-026-00874-x.
Παραπομπή σε μορφή MLA (9th εκδ.)Burmester, Gerd R., et al. "Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and Up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies." Rheumatology and Therapy, vol. 13, no. 5, 2026, p. 1287, https://doi.org/10.1007/s40744-026-00874-x.